Abstract 4096
Background
CAPRI, a randomized phase III trial comparing: an intervention combining Nurse Navigators (NNs) and a mobile application vs. Standard of care in cancer patients treated with oral anticancer agents was initiated in 2016 at Gustave Roussy (Villejuif, France). NNs provide regular telephone follow-ups to manage patients’ symptoms and assess toxicities, adherence to treatment and supportive care needs. Patients have access to a mobile application to record tracking data, contact NNs via secure messaging, view therapy and side effect information or store documents. Patient can contact the NNs on a dedicated phone line or by email/secure messaging
Methods
The present analysis involves 3 main data sources: - A questionnaire sent to patients after using for 5 months the CAPRI intervention in order to assess their experience, - Interviews conducted with patients to obtain their feedback of the intervention, - Data extraction from the application and NNs’ interventions over a 24-month period.
Results
Overall, 166 patients (83%) filled the questionnaire. Fifteen interviews were conducted. Patients’ experience with CAPRI intervention is summarized in the table below.Table: CN12
Items | % of patients strongly agree or agree |
---|---|
CAPRI intervention is useful | 96 |
Communicating with the NNs is a reassuring experience | 98 |
CAPRI intervention helps me to better manage my treatment | 79 |
CAPRI intervention is helpful in managing the side effects of my treatment | 87 |
CAPRI intervention helps me to become involved in my treatment | 81 |
CAPRI intervention responds to my expectations and needs for care | 90 |
I am satisfied with the responses from the NNs | 91 |
CAPRI intervention is overly constraining | 9 |
The open-ended comments on the questionnaires and interviews with patients highlighted the importance of listening, having a contact person who is easily reachable, available and empathetic. Concerning the use of the mobile application, 53% of patients reported having tried to connect and only 38% reported monitoring data at least once. By focusing on patient-NNs communication during the study period (817 requests), most contacts are performed by phone (78%) or e-mail (18%) but very few by secure messaging (4%).
Conclusions
Patients’ experience about the intervention was strongly positive. However, the mobile application is poorly used, suggesting that from the patients’ perspective, the presence of NNs is the key of the intervention.
Clinical trial identification
2016-A00254-47.
Editorial acknowledgement
Legal entity responsible for the study
Gustave Roussy.
Funding
Fondation Philanthropia - Lombard Odier, Agence Nationale de la Recherche IHU-MMO, ARS Ile de France, Novartis, AstraZeneca.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5705 - External validation and longitudinal extension of the LIPI (Lung Immune Prognostic Index) for immunotherapy outcomes in advanced non-small cell lung cancer.
Presenter: Jakob Riedl
Session: Poster Display session 3
Resources:
Abstract
5758 - Changes of TCR Repertoire in Metastatic Renal Cell Carcinoma and Metastatic Melanoma Patients Treated with Nivolumab
Presenter: Martin Klabusay
Session: Poster Display session 3
Resources:
Abstract
1743 - Expression of MHC class I, HLA-A and HLA-B identifies immune activated breast tumors with favorable outcome
Presenter: María Del Mar Noblejas López
Session: Poster Display session 3
Resources:
Abstract
2219 - Prognostic Significance of Tumor Tissue NeuGcGM3 Ganglioside Expression and Predictive Value of Circulating Tumor Cell Count Monitoring in Patients Receiving Racotumomab Immunotherapy
Presenter: Necdet Üskent
Session: Poster Display session 3
Resources:
Abstract
2996 - Evolution of Myeloid-Derived Suppressor Cells and Objective Response Rate in Relapsed/Refractory Diffuse Large B Cell Lymphoma (R/R DLBCL) patients after receiving immunotherapy
Presenter: Carlos Jiménez Cortegana
Session: Poster Display session 3
Resources:
Abstract
2110 - A Phase Ia/Ib trial of the anti-programmed death-ligand 1 (PD-L1) human monoclonal antibody (mAb), CS1001, in patients (pts) with advanced solid tumors or lymphomas
Presenter: Lin Shen
Session: Poster Display session 3
Resources:
Abstract
3515 - Results from a randomised Phase 1/2 trial evaluating the safety and antitumour activity of anti-PD-1 (MEDI0680)/anti-PD-L1 (durvalumab) vs anti-PD-1 (nivolumab) alone in metastatic clear cell renal cell carcinoma (ccRCC)
Presenter: Martin Voss
Session: Poster Display session 3
Resources:
Abstract
3566 - Pembrolizumab in Advanced Rare Cancers
Presenter: Aung Naing
Session: Poster Display session 3
Resources:
Abstract
3567 - High clinical benefit rates of pembrolizumab in very rare sarcoma histotypes: first results of the AcSé Pembrolizumab study
Presenter: Jean-Yves Blay
Session: Poster Display session 3
Resources:
Abstract
2421 - Lenvatinib plus PD-1 blockade in advanced bile tract carcinoma.
Presenter: Jianzhen Lin
Session: Poster Display session 3
Resources:
Abstract